Edsbäcker Staffan, Larsson Per, Wollmer Per
Experimental Medicine, AstraZeneca Pharmaceuticals LP, Wayne, Pennsylvania 19087, USA.
Eur J Gastroenterol Hepatol. 2002 Dec;14(12):1357-62. doi: 10.1097/00042737-200212000-00012.
To compare the pharmacokinetics and site of uptake of budesonide from a controlled-release formulation and a deuterium-labelled standard formulation given before and after a meal.
Six healthy volunteers were randomized into an open, crossover study. They received 4.5 mg controlled-release budesonide (mixed with In pellets to trace gastrointestinal transit) and 4.8 mg 2H8-budesonide simultaneously at each of two visits: one visit before a standardized breakfast and the other after breakfast. Plasma concentrations of budesonide were followed over 24 h. The transit of the (111)In pellets through the gastrointestinal tract was followed for 36 h. Data on the site of absorption were calculated from transit times and absorption curves.
The time to peak plasma concentration was significantly increased with controlled-release budesonide when compared with the deuterium-labelled standard formulation (before breakfast, 4.5 h vs 1.8 h; after breakfast, 5.2 h vs 2.9 h). When given after breakfast, the controlled-release formulation was associated with a mean residence time 1.6 h longer than that seen with the standard formulation. However, the areas under the plasma concentration curves were similar with the two formulations, regardless of when the treatments were given (before breakfast, 18.0 +/- 3.8 nmol/l vs 18.0 +/- 6.0 nmol/l; after breakfast, 16.9 +/- 7.0 nmol/l vs 18.5 +/- 9.0 nmol/l). Over 60% of the total budesonide absorbed from controlled-release capsules was delivered and absorbed in the ileum and colon. The corresponding proportion for the standard formulation was approximately 33%.
Controlled-release budesonide effectively delivers most of the budesonide dose to the ileum and colon, the regions that are most often affected by inflammatory bowel disease. In addition, the time of food intake has little effect on the site of absorption or the bioavailability of the controlled-release formulation. Delivery to the colon and ileum was independent of whether the drug was given before or after breakfast.
比较控释制剂和氘标记标准制剂的布地奈德在进食前后的药代动力学及摄取部位。
6名健康志愿者被随机纳入一项开放、交叉研究。在两次访视中,他们每次同时接受4.5毫克控释布地奈德(与铟颗粒混合以追踪胃肠道转运)和4.8毫克2H8 - 布地奈德:一次在标准早餐前,另一次在早餐后。在24小时内监测布地奈德的血浆浓度。追踪(111)铟颗粒在胃肠道内的转运36小时。根据转运时间和吸收曲线计算吸收部位的数据。
与氘标记标准制剂相比,控释布地奈德的血浆浓度达峰时间显著延长(早餐前,4.5小时对1.8小时;早餐后,5.2小时对2.9小时)。早餐后给药时,控释制剂的平均驻留时间比标准制剂长1.6小时。然而,无论何时给药(早餐前,18.0±3.8纳摩尔/升对18.0±6.0纳摩尔/升;早餐后,16.9±7.0纳摩尔/升对18.5±9.0纳摩尔/升),两种制剂的血浆浓度曲线下面积相似。从控释胶囊吸收的布地奈德总量中,超过60%在回肠和结肠递送并吸收。标准制剂的相应比例约为33%。
控释布地奈德能有效地将大部分布地奈德剂量递送至回肠和结肠,这些部位是炎症性肠病最常累及的区域。此外,进食时间对控释制剂的吸收部位或生物利用度影响很小。药物递送至结肠和回肠与早餐前或早餐后给药无关。